The FDA has lifted a partial clinical hold on Icagen's photosensitive epilepsy drug ICA-105665. The agency had placed the hold on the drug back in March as a result of some preclinical data. Icagen is now planning proof-of-concept trials of the drug for both epipelpsy and pain. Release